Pfizer CSO Mikael Dolsten to Step Down After 15 Years Driving R&D 7/9/2024

FDA CBER Director Dr. Peter Marks Discusses Industry Growth, Collaboration and Communication 7/9/2024

US Government Files Appeal in High-Stakes HIV PrEP Patent Battle Against Gilead 7/9/2024

What Does Wegovy’s Launch in China Mean as Biosimilar Competition Emerges? 7/9/2024

Roche Reintroduces Wet AMD Eye Implant Nearly Two Years After Voluntary Recall 7/9/2024

UniQure Wins First FDA RMAT in Huntington’s Disease After Strong Phase I/II Data 7/9/2024

Scientists at Harvard Medical School have designed a versatile, ChatGPT-like AI model capable of performing an array of diagnostic tasks across multiple forms of cancers.

The new AI system, described Sept. 4 in Nature, goes a step beyond many current AI approaches to cancer diagnosis, the researchers said.

Current AI systems are typically trained to perform specific tasks - such as detecting cancer presence or predicting a tumor's genetic profile - and they tend to work only in a handful of cancer types.

Stroke patients who survive a blood clot in the brain's blood vessels are prone to developing new blockages during their recovery periods, even if they receive vessel-clearing interventions. In an effort to avoid further clots, doctors at 57 sites around the U.S. tested a possible solution: the addition of anti-coagulant drugs to medicine that dissolves blood clots.

But results from the clinical trial, led by Opeolu Adeoye, MD, head of the Department of Emergency Medicine at Washington University School of Medicine in St. Louis, indicate two such drugs did not improve outcomes.

Novo Inks $600M Deal with Metaphore to Develop Next-Gen Obesity Drugs 5/9/2024

Takeda Lowers Profit Outlook Amid Vyvanse Loss of Exclusivity, Eyes $900M Restructuring in 2024 5/9/2024

Women's Health: Where Politics and Science Meet 5/9/2024

Attovia Secures $105M Series B to Expand I&I Pipeline of Bispecific Antibodies 5/9/2024

Lisata’s Autologous T Cell Therapy Is Safe but Fails to Slow T1D Disease Progression, Trial Finds 5/9/2024

Bespoke Gene Therapy Consortium Targets AAVs for Rare Diseases 5/9/2024

Keytruda Strikes Out Again in Endometrial Cancer with Phase III Flop 5/9/2024

DEIB Evolves As Criticism, Changing Attitudes Continue 5/9/2024

Dry Promotions: Dealing With a Double-Edged Sword 5/9/2024

Top 5 Companies Hiring in the Boston Area 5/9/2024

Investigators involved in a multicenter study co-led by Cedars-Sinai discovered a pathway by which immune cells prevent the lungs' protective barrier from healing after viral infections like COVID-19. The findings, published in Nature may lead to new therapeutic treatment options.

The COVID-19 pandemic revealed how viral infections can cause long-lasting effects - a condition called long COVID. Also known as post-acute sequelae of SARS-CoV-2, long COVID has left a devastating trail of people who continue to live with long-term debilitation after infection.

Pfizer Eyes Broader Label for RSV Vaccine Abrysvo After Promising Phase III Data 4/9/2024